NCT01972516View on ClinicalTrials.gov

Tivozanib As Maintenance Therapy In GYN

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

January 31, 2016

Conditions
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Interventions
DRUG

Tivozanib

Trial Locations (1)

02215

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

collaborator

AVEO Pharmaceuticals, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER